Evidence map›Paper›PMID 31339234›Full record

ArticleCancer medicine2019

Oridonin induces Mdm2-p60 to promote p53-mediated apoptosis and cell cycle arrest in neuroblastoma.

Han-Qing Zhu, Chao Zhang, Zhu-Ying Guo, Jun-Mei Yang, Jia-Hui Guo, Chen Chen, Qiang-Hua Yao, Feng Liu, Quan-Wu Zhang, Feng-Hou Gao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Oridonin fromFood science & nutrition · 2024
    Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Han-Qing ZhuDepartment of Oncology, Shanghai 9th People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Chao ZhangDepartment of Geriatrics, Shanghai 9th People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhu-Ying GuoDepartment of Oncology, Shanghai 9th People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Jun-Mei YangDepartment of Clinical Laboratory, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou, China.
Jia-Hui GuoDepartment of Oncology, Shanghai 9th People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Chen ChenDepartment of Oncology, Shanghai 9th People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Qiang-Hua YaoDepartment of Pediatrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Feng LiuDepartment of Oncology, Shanghai 9th People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Quan-Wu ZhangDepartment of Pathology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, China.
Feng-Hou GaoDepartment of Oncology, Shanghai 9th People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID https://orcid.org/0000-0001-5032-6955
Shanghai Jiao Tong University · CNFirst Affiliated Hospital of Zhengzhou University · CNZhengzhou Central Hospital · CNZhengzhou University · CN

Funding

Science and Technology Committee of Baoshan District 12-E-2Science and Technology Committee of Shanghai 14401901500Shanghai Municipal Education Committee 13ZZ089The National Natural Science Foundation of China 81172322The National Natural Science Foundation of China 81302006The National Natural Science Foundation of China 81572796
6 · The paper itself

Abstract

Oridonin could induce NB (neuroblastoma) cells growth inhibition by inducing apoptosis and cell cycle arrest, and the molecular mechanisms behind the effects deserve to be further explored. Here, oridonin was confirmed to cause the reactivation of p53 (cellular tumor antigen p53) to promote the expression of a series of apoptosis- and cell cycle arrest-related proteins for the biological effects. During the process, oridonin relied on the caspase activation to cleave p53-induced Mdm2 (E3 ubiquitin-protein ligase Mdm2) to generate Mdm2-p60. The generation of Mdm2-p60 stabilized p53, and resulted in p53 accumulation for p53 continuous activation. In our research, it was also found that the reactivation of p53 induced by oridonin was closely related with the generation of ROS (reactive oxygen species). Taken together, these findings explain that oridonin exerts its anticancer activity partially by targeting the Mdm2-p53 axis in NB cells, which lay an experimental base for future research of exploring the effects and molecular mechanisms of oridonin.

Indexed as

AnimalsAntineoplastic Agents, PhytogenicApoptosisCell Cycle CheckpointsCell Line, TumorCell ProliferationCyclin-Dependent Kinase Inhibitor p21Disease Models, AnimalDiterpenes, KauraneFemaleHumansMiceModels, BiologicalNeuroblastomaProto-Oncogene Proteins c-mdm2Reactive Oxygen SpeciesAntineoplastic Agents, PhytogenicCDKN1A protein, humanCyclin-Dependent Kinase Inhibitor p21Diterpenes, KauraneMDM2 protein, humanoridoninProto-Oncogene Proteins c-mdm2Reactive Oxygen SpeciesTP53 protein, humanTumor Suppressor Protein p53apoptosiscell cycle arrestMdm2-p60Oridoninp53ROS

Identifiers

PMID31339234
PMCPMC6718599
OpenAlexW2963763117

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.